Cyclo-Oxygenase 2 Inhibitors Pipeline Insight, 2022 report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Cyclo-Oxygenase 2 Inhibitors development.

Cyclo-Oxygenase 2 Inhibitors Pipeline Drug Insights Report

DelveInsight&rsquo;s, &ldquo;Cyclo-Oxygenase 2 Inhibitors - Pipeline Insight, 2025,&rdquo; report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Cyclo-Oxygenase 2 Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
<h2>Geography Covered</h2>
<ul>
<li>Global coverage</li>
</ul>
<h2>Cyclo-Oxygenase 2 Inhibitors Understanding</h2>
Cyclo-Oxygenase 2 Inhibitors: Overview
COX-2 inhibitors are a type of nonsteroidal anti-inflammatory drug (NSAID) that directly targets cyclooxygenase-2, COX-2, an enzyme responsible for inflammation and pain. Targeting selectivity for COX-2 reduces the risk of peptic ulceration and is the main feature of celecoxib, rofecoxib, and other members of this drug class. COX-2 appears to be related to cancers and abnormal growths in the intestinal tract. COX inhibitors have been shown to reduce the occurrence of cancers and pre-cancerous growths. COX-2 inhibitors have been found to be effective in suppressing inflammatory neurodegenerative pathways in mental illness, with beneficial results in trials for major depressive disorder as well as schizophrenia. The inhibition of COX-2 is paramount for the anti-inflammatory and analgesic function of the selective COX-2 inhibitor celecoxib.
<h2>Report Highlights</h2>
The companies and academics are working to assess challenges and seek opportunities that could influence Cyclo-Oxygenase 2 Inhibitors R&amp;D. The therapies under development are focused on novel approaches for Cyclo-Oxygenase 2 Inhibitors.
<h2>Cyclo-Oxygenase 2 Inhibitors Emerging Drugs Chapters</h2>
This segment of the Cyclo-Oxygenase 2 Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
&nbsp;
Cyclo-Oxygenase 2 Inhibitors Emerging Drugs
&nbsp;
Bardoxolone methyl: Reata Pharmaceuticals
Bardoxolone is an investigational, once-daily, orally administered activator of Nrf2, a transcription factor that induces molecular pathways that promote the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. The FDA has granted Orphan Drug designation to bardoxolone for the treatment of Alport syndrome and autosomal dominant polycystic kidney disease (&ldquo;ADPKD&rdquo;). The European Commission has granted Orphan Drug designation in Europe to bardoxolone for the treatment of Alport syndrome.
&nbsp;
ALLOD-2: Allodynic Therapeutics
Allodynic Therapeutics is a clinical-stage biopharma company engaged in developing an oral novel investigational therapeutic product candidate, naltrexone-acetaminophen (ALLOD-2), for the acute treatment of migraine. Naltrexone-acetaminophen is a non-addictive medication that can also potentially be effective for the preventive treatment of migraine and neuropathic pain. Naltrexone-acetaminophen combines naltrexone&rsquo;s under-recognized analgesic properties with acetaminophen&rsquo;s under-recognized emotional pain calming properties, simultaneously targeting physical and emotional pain, hence, enhancing the treatment outcomes. In addition, naltrexone-acetaminophen portrays two innovative features, naltrexone&rsquo;s novel inhibition of the Toll-Like receptor-4 (TLR4) leading to the reversal of neuropathic pain with acetaminophen&rsquo;s ability to potentiate other analgesics beyond its own contribution (e.g., creating a potential analgesic synergism). Naltrexone-acetaminophen has U.S. patents extending to 2037.
Further product details are provided in the report&hellip;&hellip;..
<h2>Cyclo-Oxygenase 2 Inhibitors: Therapeutic Assessment</h2>
This segment of the report provides insights about the different Cyclo-Oxygenase 2 Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
<ul>
<li>Major Players working on Cyclo-Oxygenase 2 Inhibitors</li>
</ul>
There are approx. 25+ key companies which are developing the Cyclo-Oxygenase 2 Inhibitors. The companies which have their Cyclo-Oxygenase 2 Inhibitors drug candidates in the most advanced stage, i.e. Preregistration include, Reata Pharmaceuticals.
<h2>Phases</h2>
DelveInsight&rsquo;s report covers around 25+ products under different phases of clinical development like
<ul>
<li>Late-stage products (Phase III and</li>
<li>Mid-stage products (Phase II and</li>
<li>Early-stage products (Phase I/II and Phase I) along with the details of</li>
<li>Pre-clinical and Discovery stage candidates</li>
<li>Discontinued &amp; Inactive candidates</li>
<li>Route of Administration</li>
</ul>
&nbsp;
Cyclo-Oxygenase 2 Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 
<ul>
<li>Infusion</li>
<li>Intradermal</li>
<li>Intramuscular</li>
<li>Intranasal</li>
<li>Intravaginal</li>
<li>Oral</li>
<li>Parenteral</li>
<li>Subcutaneous</li>
<li>Topical</li>
<li>Molecule Type</li>
</ul>
&nbsp;
Products have been categorized under various Molecule types such as
<ul>
<li>Vaccines</li>
<li>Monoclonal Antibody</li>
<li>Peptides</li>
<li>Polymer</li>
<li>Small molecule</li>
<li>Product Type</li>
</ul>
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
<h2>Cyclo-Oxygenase 2 Inhibitors: Pipeline Development Activities</h2>
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Cyclo-Oxygenase 2 Inhibitors therapeutic drugs key players involved in developing key drugs.
&nbsp;
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cyclo-Oxygenase 2 Inhibitors drugs.
<h2>Cyclo-Oxygenase 2 Inhibitors Report Insights</h2>
<ul>
<li>Cyclo-Oxygenase 2 Inhibitors Pipeline Analysis</li>
<li>Therapeutic Assessment</li>
<li>Unmet Needs</li>
<li>Impact of Drugs</li>
</ul>
<h2>Cyclo-Oxygenase 2 Inhibitors Report Assessment</h2>
<ul>
<li>Pipeline Product Profiles</li>
<li>Therapeutic Assessment</li>
<li>Pipeline Assessment</li>
<li>Inactive drugs assessment</li>
<li>Unmet Needs</li>
</ul>
<h2>Key Questions</h2>
Current Scenario and Emerging Therapies:
<ul>
<li>How many companies are developing Cyclo-Oxygenase 2 Inhibitors drugs?</li>
<li>How many Cyclo-Oxygenase 2 Inhibitors drugs are developed by each company?</li>
<li>How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cyclo-Oxygenase 2 Inhibitors?</li>
<li>What are the key collaborations (Industry&ndash;Industry, Industry&ndash;Academia), Mergers and acquisitions, licensing activities related to the Cyclo-Oxygenase 2 Inhibitors therapeutics?</li>
<li>What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?</li>
<li>What are the clinical studies going on for Cyclo-Oxygenase 2 Inhibitors and their status?</li>
<li>What are the key designations that have been granted to the emerging drugs?</li>
</ul>

Introduction
Executive Summary
Cyclo-Oxygenase 2 Inhibitors: Overview
<ul>
<li>Structure</li>
<li>Mechanism of Action</li>
</ul>
Pipeline Therapeutics
<ul>
<li>Comparative Analysis</li>
</ul>
Therapeutic Assessment
<ul>
<li>Assessment by Product Type</li>
<li>Assessment by Stage and Product Type</li>
<li>Assessment by Route of Administration</li>
<li>Assessment by Stage and Route of Administration</li>
<li>Assessment by Molecule Type</li>
<li>Assessment by Stage and Molecule Type</li>
</ul>
Cyclo-Oxygenase 2 Inhibitors &ndash; DelveInsight&rsquo;s Analytical Perspective
Late Stage Products (Preregistration) 
<ul>
<li>Comparative Analysis</li>
</ul>
Bardoxolone methyl: Reata Pharmaceuticals
<ul>
<li>Product Description</li>
<li>Research and Development</li>
<li>Product Development Activities</li>
</ul>
Drug profiles in the detailed report&hellip;..
Mid Stage Products (Phase II)
<ul>
<li>Comparative Analysis</li>
</ul>
DRGT 46: Tavanta Therapeutics
<ul>
<li>Product Description</li>
<li>Research and Development</li>
<li>Product Development Activities</li>
</ul>
Drug profiles in the detailed report&hellip;..
Early Stage Products (Phase I) 
<ul>
<li>Comparative Analysis</li>
</ul>
OX338: Orexo
<ul>
<li>Product Description</li>
<li>Research and Development</li>
<li>Product Development Activities</li>
</ul>
Drug profiles in the detailed report&hellip;..
Pre-clinical and Discovery Stage Products
<ul>
<li>Comparative Analysis</li>
</ul>
NTM 004: Neumentum
<ul>
<li>Product Description</li>
<li>Research and Development</li>
<li>Product Development Activities</li>
</ul>
Drug profiles in the detailed report&hellip;..
Inactive Products
<ul>
<li>Comparative Analysis</li>
</ul>
Cyclo-Oxygenase 2 Inhibitors Key Companies
Cyclo-Oxygenase 2 Inhibitors Key Products
Cyclo-Oxygenase 2 Inhibitors- Unmet Needs
Cyclo-Oxygenase 2 Inhibitors- Market Drivers and Barriers
Cyclo-Oxygenase 2 Inhibitors- Future Perspectives and Conclusion
Cyclo-Oxygenase 2 Inhibitors Analyst Views
Cyclo-Oxygenase 2 Inhibitors Key Companies
Appendix

Cyclo-Oxygenase 2 Inhibitors - Pipeline Insight, 2025

"Cyclo-Oxygenase 2 Inhibitors" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action.